Skip to main content

Research

 

The Center and its core facilities have been instrumental in developing public and private partnerships and have played a key role developing and submitting to federal agencies cross-disciplinary grant applications for research on nanomedicine technologies including successful renewal of the Carolina Center of Cancer Nanotechnology Excellence (CCNE) and establishment of the Carolina Cancer Nanotechnology Training Program (C-CNTP).

  1. Biomaterials to Study Tolerance Immune Induction Kinetics
    R01AI137525
    NIAID, 08/14/2018 – 07/31/2023; Role: PI
  2. Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
    R01AI141333
    NIAID, 12/14/2018 – 11/30/2023; Role: Co-Investigator
  3. Center for Influenza Vaccine Research in High Risk Populations
    SUB00002146-3A
    University of Georgia Research Foundation, 09/10/2019 – 09/09/2022; Role: PI
  4. Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
    R01AI147497
    NIAID, 01/15/2020 – 12/31/2024; Role: PI
  5. Formulation to Generate Tolerance Towards Type 1 Diabetes
    R01DK130225
    NIDDK, 07/01/2021 – 04/30/2025; Role: PI
  6. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: PI
  1. Biomaterials to Study Tolerance Immune Induction Kinetics
    R01AI137525
    NIAID, 08/14/2018 – 07/31/2023; Role: Co-Investigator
  2. Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
    R01AI141333
    NIAID, 12/14/2018 – 11/30/2023; Role: Co-PI
  3. Center for Influenza Vaccine Research in High Risk Populations
    SUB00002146-3A
    University of Georgia Research Foundation, 09/10/2019 – 09/09/2022; Role: Co-Investigator
  4. Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
    R01AI147497
    NIAID, 01/15/2020 – 12/31/2024; Role: Co-Investigator
  5. Formulation to Generate Tolerance Towards Type 1 Diabetes
    R01DK130225
    NIDDK, 07/01/2021 – 04/30/2025; Role: Co-Investigator
  6. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: Co-Investigator
  1. Cell-Mediated Targeted Redox Intervention for the Treatment and Prevention of Atherosclerosis
    K01HL145354
    NHLBI, 12/15/2019 – 11/30/2023; Role: PI
  1. Cell-Based Platform for Gene Delivery to the Brain
    R01NS102412
    NINDS, 03/01/2018 – 11/30/2022; Role: PI
  2. Extracellular Vesicles for CNS Delivery of Therapeutic Enzymes to Treat Lysosomal Storage Disorders
    R01NS112019
    NINDS, 09/01/2019 – 06/30/2024; Role: PI
  3. A targeted anti-HIV drug delivery to the GALT
    R01AI147731
    NIAID, 07/16/2020 – 06/30/2025; Role: Co-Investigator
  1. Next Generation Ultra-Long Acting Antiretroviral Formulations for HIV Treatment and Prevention
    R01AI140799
    NIAID, 09/24/2018 – 08/31/2023; Role: Co-Investigator
  2. Ultra-Long Acting In-Situ Forming Implant (ISFI) for Antiretroviral Drug Delivery, incl. EFdA
    OPP1203712
    Bill and Melinda Gates Foundation, 08/05/2019 – 10/31/2022; Role: Co-Investigator
  3. In vivo evaluation of safety and pharmacology of the sustained release formulation of dolutegravir in pre-conception and early stages of pregnancy
    R01HD100584
    NICHD, 09/13/2019 – 07/31/2024; Role: Co-Investigator
  4. Next Generation Multipurpose Intravaginal Ring Technology Using Innovative CLIP 3D Printing
    R01AI150358
    NIAID, 12/01/2019 – 11/30/2024; Role: PI
  5. Ultra-Long-Acting Polymeric Injectable Multi-Purpose Prevention Technology for Contraception and HIV Prevention
    R01AI162246
    NIAID, 04/13/2021 – 03/31/2026; Role: PI
  6. Injectable, Biodegradable, Removable Long-Acting In-situ Forming Implant for Sustained Delivery of Non-Hormonal Male Contraceptives
    2021-202
    Male Contraception Initiative, 06/01/2021 – 05/31/2023; Role: PI
  1. Image-Guided, Ultrasound-Enhanced Long-Term Intracranial Drug Delivery
    R21CA246414
    NCI, 02/15/2020 – 01/31/2023; Role: Co-PI
  2. Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production
    R37CA260223
    NCI, 04/16/2021 – 03/31/2026; Role: PI
  1. Academic-Industrial Partnership for Translation of Acoustic Angiography
    R01CA189479
    NCI, 09/04/2014 – 08/31/2026; Role: PI
  2. High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
    R01CA220681
    NCI, 09/04/2014 – 08/31/2026; Role: PI
  3. Treating Tumoral Hypoxia via Ultrasound-Guided Oxygen Release for Improving Radiation Therapy
    R01CA232148
    NCI, 06/01/2018 – 05/31/2024; Role PI
  4. Acoustic Angiography Using Dual-Frequency and Ultrawideband CMUT Arrays
    R01EB026897
    NIBIB, NC State University, 07/01/2018 – 03/31/2023; Role: Co-PI
  5. Next Generation Ultra-Long Acting Antiretroviral Formulations for HIV Treatment and Prevention
    R01AI140799
    NIAID, 09/24/2018 – 08/31/2023; Role: Co-Investigator
  6. Image-Guided, Ultrasound-Enhanced Long-Term Intracranial Drug Delivery
    R21CA246414
    NCI, 02/15/2020 – 01/31/2023; Role: Co-PI
  7. Parametric Optimization of Ultrasound-Mediated Immuno-Modulation for Pancreatic Cancer Therapy
    R21CA246550
    NCI, 04/01/2020 – 03/31/2023; Role: Co-PI
  8. Gas microbubbles as a hyperpolarized-xenon carrier and as a contrast agent for MRI
    R21EB031319
    NIBIB, 04/01/2021 – 01/31/2023; Role: Co-Investigator
  1. Selective Targeting Reactive Oxygen Species for Age-Related Macular Degeneration
    M2019063
    BrightFocus Foundation, 07/01/2019 – 06/30/2022; Role: PI
  1. Nanofiber Matrices to Improve Neural Stem Cell-Mediated Cancer Therapy
    R01NS097507
    NINDS, 06/01/2016 – 05/31/2022; Role: PI
  2. Engineering Stem Cell Therapies to Understand and Overcome Glioblastoma Adaption
    R01NS099368
    NINDS, 09/26/2017 – 06/30/2022; Role: PI
  3. A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
    U01TR003715
    NCATS, 07/01/2021 – 04/30/2025; Role: Co-PI
  4. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: Co-Investigator
  5. Nanoformulated small molecule immunotherapy for SHH medulloblastoma
    R01NS125073
    NINDS, 01/01/2022 – 12/31/2026; Role: Co-Investigator
  6. Harnessing Continuous Liquid Interface 3D Printing to Improve Tumor-homing Stem Cell Therapy for Post-surgical Brain Cancer
    R01CA269974
    NCI, 02/01/2022 – 01/31/2027; Role: Co-PI
  1. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    T32CA196589
    NCI, 07/01/2015 – 06/30/2025; Role: Director
  2. Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors
    R01CA247652
    NCI, 04/01/2021 – 03/31/2026; Role: Co-Investigator
  3. Toward Translation of Nanformulated Paclitaxel-Platinum Combination
    R01CA264488
    NCI, 08/01/2021 – 07/31/2025, Role: PI
  1. Overcoming anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
    R01HL141934
    NHLBI, 05/10/2018 – 04/30/2023; Role: Co-PI
  2. Dynamic Tuning of Barrier Properties of Hydrogels Using Weakly Adhesive Third-Party Crosslinkers
    DMR-1810168
    NSF, 08/01/2018 – 07/31/2022; Role: PI
  3. Capsule-Intravaginal Ring Providing Sustained Release of Antibodies for Non-Hormonal Contraception and Prevention of Vaginal HIV Transmission
    R44HD097063
    NICHD, Mucommune, 04/01/2021 – 03/31/2023; Role: Co-Investigator
  4. Engineering Bispecific Antibodies for Non-Hormonal Contraception
    R01HD101562
    NICHD, 04/01/2020 – 03/31/2024; Role: PI
  5. Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal ContraceptionR01HD101344
    NICHD, 05/05/2020 – 02/28/2025; Role: Co-PI
  1. Trimerization of the N-terminal Domain of ACE2 for Bifunctional Trapping of Future SARS-CoV-2 Variants
    R21AI163793
    NIAID, 07/09/2021 – 06/30/2023; Role: PI
  1. Cellular Networks for Enhanced Drug Retention and Accumulation at Target Site
    21-1006
    PhRMA, 01/01/2021 – 12/31/2022; Role: PI
  2. CAREER: Active-Loadable Poresomes for the Cytoplasmic Delivery of Membrane-Impermeable Compounds
    2000256
    NSF, 07/01/2019 – 04/30/2023; Role: PI
  3. Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
    21-1006
    PhRMA, 01/01/2021 – 12/31/2022; Role: PI
  1. Immune Regulation of Lung Squamous Metastasis
    R01CA215075
    NCI, 09/21/2017 – 08/31/2022; Role: PI
  2. Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
    R01CA258451
    NCI, 03/01/2021 – 02/28/2026; Role: Co-PI
  1. BCL-xL-regulated Apoptosis in Cerebellar Development and Medulloblastoma Treatment
    R01NS102627
    NINDS, 06/01/2018 – 04/30/2023; Role: Co-Investigator
  2. Toward Translation of Nanformulated Paclitaxel-Platinum Combination
    R01CA264488
    NCI, 08/01/2021 – 07/31/2025, Role: Co-Investigator
  3. Nanoformulated small molecule immunotherapy for SHH medulloblastoma
    R01NS125073
    NINDS, 01/01/2022 – 12/31/2026; Role: PI
  1. Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-Based Macrocycles
    R35GM125005
    NIGMS, 09/05/2017 – 08/31/2022; Role: Co-Investigator
  2. ARAGORN: Autonomous Relay Agent for Generation Of Ranked Networks
    OT2TR003441
    NCATS, 01/23/2020 – 11/30/2022; Role: Co-PI
  3. Enabling the Accelerated Discovery of Novel Chemical Probes by Integration of Crystallographic, Computational, and Synthetic Chemistry Approaches
    R01GM140154
    NIGMS, 05/01/2021 – 04/30/2025; Role: Co-PI
  4. STopTox: A comprehensive in silico platform for predicting systemic and topical toxicity
    R41ES033589
    NIEHS, 08/13/2021 – 07/31/2022; Role: PI
  5. Artificial Intelligence Toolkit for Predicting Mixture Toxicity
    R41ES033857
    NIEHS, 12/20/2021 – 11/30/2022; Role: PI
  1. Overcoming Anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
    R01HL141934
    NHLBI, 05/10/2018 – 04/30/2022; Role: PI
  2. Design and Application of Photoresponsive Modules in Circulating Erythrocytes
    R01HL153744
    NHLBI, 05/01/2021 – 04/30/2025; Role: Co-Investigator
  3. Toward Translation of Nanformulated Paclitaxel-Platinum Combination
    R01CA264488
    NCI, 08/01/2021 – 07/31/2025, Role: Co-Investigator
  4. Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
    R01CA257009
    NCI, 08/01/2021 – 07/31/2026; Role: Co-Investigator
  5. Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors
    R01CA247652
    NCI, 04/01/2021 – 03/31/2026; Role: Co-PI

 

Kristy Ainslie

Eric Michael Bachelder

Edward Moreira Bahnson

Elena V. Batrakova

Owen S. Fenton

Zongchao Han

Shawn D. Hingtgen

Leaf Huang

Alexander V. Kabanov

Sam Lai

Rihe Liu

Juliane Nguyen

Chad V. Pecot

Marina Sokolsky

Alexander Tropsha

William Zamboni